Dr. Pere Santamaria
MD, Ph.D
Positions
Professor
Cumming School of Medicine, Department of Microbiology, Immunology and Infectious Diseases
Chair
Julia McFarlane Diabetes Research Centre
Full Member
The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Immunology Research Group
Associate Member
Hotchkiss Brain Institute
Full Member
The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases
Contact information
Research
Areas of Research
Autoimmunity, Antigen-specific Therapy, Nanotechnology
Participation in university strategic initiatives
Publications
- A mechanism for the Major Histocompatibility Complex-linked resistance to autoimmunity. Schmidt D, Verdaguer J, Averill N, Santamaria P.. Journal of Experimental Medicine. 186 (7): 1059-1075. (1997)
- Spontaneous autoimmune diabetes in monoclonal T-cell NOD Mice. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P.. Journal of Experimental Medicine. 186 (10): 1663-1676. (1997)
- Prevalent CD8+ T cell response against one peptide/MHC complex in autoimmune diabetes. Anderson B, Park B-J, Amrani A, Verdaguer J, Bou S, Santamaria P.. PNAS. 96 (16): 9311-9316. (1999)
- Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P.. Nature. 406: 739–742. (2000)
- CD154-dependent priming of diabetogenic CD4+ T-cells dissociated from activation of Antigen-Presenting Cells. Amrani A, Serra P, Yamanouchi J, Han B, Thiessen S, Verdaguer J, Santamaria P.. Immunity. 16 (5): 719-732. (2002)
- CD40 ligation releases immature dendritic cells from the control of regulatory CD4+ CD25+ T-cells. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, Verdaguer P, Santamaria, P.. Immunity. 19 (6): 877-889. (2003)
- Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Han B, Serra P, Amrani A, Yamanouchi J, Marée AF, Edelstein-Keshet L, Santamaria P.. Nature Medicine. 11: 645–652. (2005)
- Developmental control of CD8+ T-cell avidity maturation in autoimmune diabetes. Han B, Serra P, Yamanouchi J, Amrani A, Elliott JF, Dickie P, Dilorenzo TP, Santamaria P.. Journal of Clinical Investigation. 115 (7): 1879–1887. (2005)
- Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P.. Nature Genetics. 39: 329–337. (2007)
- Reversal of autoimmunity by boosting memory-like autoregulatory T-cells. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, Yang Y, Medarova Z, Moore A, Santamaria P.. Immunity. 32 (4): 568-580. (2010)
- In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation. Wang J, Tsai S, Shameli A, Yamanouchi J, Alkemade G, Santamaria P. . PNAS. 107 (20): 9317-9322. (2010)
- Antidiabetogenic MHC class II promotes the differentiation of MHC-promiscuous autoreactive T cells into FOXP3+ regulatory T cells. Tsai S, Serra-Devecchi P, Clemente-Casares X, Yamanouchi J, Thiessen S, Slattery RM, Elliott JF, Santamaria P.. PNAS. 110 (9): 3471-3476. (2013)
- Expanding antigen-specific regulatory networks to treat autoimmunity. Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C, Agrawal S, Keough MB, Yong VW, James E, Moore A, Yang Y, Stratmann T, Serra P, Santamaria P.. Nature. 530: 434–440. (2016)
- Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices. Singha, S, Shao K, Yang Y, Clemente-Casares, X, Clemente A, Blanco J, Dai Q, Liu SW, Yamanouchi J, Umeshappa C, Nanjundappa R, Detampel P, Amrein M, Fandos C, Tanguay R, Newbigging S, Serra P, Khadra A, Chan WCW, Santamaria P.. Nature Nanotechnology. 12: 701–710. (2017)
- A gut microbial mimic that hijacks diabetogenic autoreactivity to suppress colitis. Nanjundappa, R, Ronchi, F, Wang, J, Clemente-Casares, X, Yamanouchi, J, Umeshappa, K, Yang, Y, Blanco, J, Bassolas-Molina, H, Salas, A, Khan, H, Slattery, RM, Wyss, M, Mooser, K, Macpherson, AJ, Sycuro, LK, Serra, P, McKay, DM, McCoy, KD, Santamaria, P.. Cell. 171 (3): 655-667. (2017)
- Antigen-specific therapeutic approaches for autoimmunity. Serra, P., Santamaria, P.. Nature Biotechnology. 37: 238–251. (2019)
- Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines. Sokke Umeshappa C, Singha S, Blanco J, Lee J, Shao K, Nanjundappa R, Yamanouchi J, Parés A, Serra P, Yang Y, Santamaria P.. Nature Communications. 10: 2150. (2019)
- Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules. Serra P, Garabatos, N, Singha, S, Fandos, C, Garnica, J, Sole P, Parras D, Yamanouchi J, Blanco J, Tort M, Ortega M, Yang Y, Ellestad KE, Santamaria P.. Nature Communications. 10: 4917. (2019)
- Ubiquitous antigen-specific T-regulatory type 1 cells variably suppress hepatic and extra-hepatic autoimmunity. Sokke Umeshappa K, Singha S, Yamanouchi J, Hebbandi Nanjundappa R, Shao K, Christen U, Yang Y, Ellestad KE, Santamaria P.. Journal of Clinical Investigation. 130 (4):1823–1829. (2020)
- Liver-specific T-regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP. Sokke Umeshappa, K., Solé, P., Surewaard, B.G.J, Mohapatra, S., Yamanouchi, J., Ortega, M., Singha, S., Mondal, D., Yang, Y., Vignali, D.A.A., Serra, P., Kubes, P. and Santamaria, P.. Cell Reports. 34 (13): 108919. (2021)
More Information
Brian Kitagawa
HRIC 4A08
Email: brian.kitagawa1@ucalgary.ca
Phone: 403.220.4220
Are you the profile owner?
Login to edit.